PAX-101 (IV suramin)

About PaxMedica

PaxMedica is dedicated to developing innovative therapies for complex neurological conditions, with a primary focus on Autism Spectrum Disorder (ASD). The company's strategy centers on repurposing and developing PAX-101, a novel formulation of suramin, based on research into the purinergic signaling pathway's role in neuroinflammation. Its most advanced program is in Phase 3 development for ASD, positioning it as a potential first-in-class therapeutic for core symptoms. The company operates as a lean, publicly-traded entity navigating the challenges of clinical development in a high-need, competitive neurological space.

About PaxMedica

PaxMedica is dedicated to developing innovative therapies for complex neurological conditions, with a primary focus on Autism Spectrum Disorder (ASD). The company's strategy centers on repurposing and developing PAX-101, a novel formulation of suramin, based on research into the purinergic signaling pathway's role in neuroinflammation. Its most advanced program is in Phase 3 development for ASD, positioning it as a potential first-in-class therapeutic for core symptoms. The company operates as a lean, publicly-traded entity navigating the challenges of clinical development in a high-need, competitive neurological space.

About PaxMedica

PaxMedica is dedicated to developing innovative therapies for complex neurological conditions, with a primary focus on Autism Spectrum Disorder (ASD). The company's strategy centers on repurposing and developing PAX-101, a novel formulation of suramin, based on research into the purinergic signaling pathway's role in neuroinflammation. Its most advanced program is in Phase 3 development for ASD, positioning it as a potential first-in-class therapeutic for core symptoms. The company operates as a lean, publicly-traded entity navigating the challenges of clinical development in a high-need, competitive neurological space.

Therapeutic Areas